Page 11 - Contract Development News Today

Ludwig de Mot appointed Chief Executive Officer Strategic Review outcome: launch of the FOCUS-27 project to improve competitiveness and unlock sustainable & profitable growth Full-Year 2023...

28.02.2024 - Ludwig de Mot appointed Chief Executive Officer Strategic Review outcome: launch of the FOCUS-27 project to improve competitiveness and unlock sustainable & profitable growth Full-Year 2023 results: resilience in a challenging business ...

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to their clients, to convert the drug substance produced at its state-of-the-art Adelaide, South Australia facility into ready-to

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to their clients, to convert the drug substance produced at its state-of-the-art Adelaide, South Australia facility into ready-to

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it...

AtomVie, together with RLS and UPPI will bolster its distribution capabilities and allow life-saving treatments to reach more patients.

Genezen Enters Licensing Agreement with CSL for the Cytegrity™ Stable Lentivirus Production System

The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.The course, which will e

NEW YORK, Feb. 16, 2024 -- Sharps Technology, Inc., , an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...